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ORIGINAL ARTICLE
Safety of Abatacept in Rheumatoid Arthritis With
Serologic Evidence of Past or Present Hepatitis B
Virus Infection
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ELEONORA CELLETTI,6 LEOPOLDO GIANI,7 PAOLA TOMIETTO,8 FABIOLA ATZENI,9
PIERCARLO SARZI PUTTINI,9 FRANCESCA ZULIANI,10 SALVATORE DE VITA,10
FRANCESCO TROTTA,1 ANASTASIO GRILLI,1 MASSIMO PUOTI,4 AND MARCELLO GOVONI1
Objective. Rheumatoid arthritis (RA) with concomitant hepatitis B virus (HBV) infection represents a therapeutic chal-
lenge due to the risk of HBV reactivation under immunosuppressive treatment. To date there are few data coming from
anecdotal case reports that concern HBV reactivation following treatment with abatacept. This observational retrospec-
tive study was aimed to assess the safety profile of abatacept in this particular clinical setting.
Methods. Eleven Italian rheumatologic centers provided data from patients with RA and positive HBV serology treated with
intravenous abatacept. HBVmarkers and clinical and laboratory data were checked at followup visits every 3months.
Results. In total, 72 patients were included in the study: 47 inactive carriers, 21 occult carriers, and 4 chronic active car-
riers for HBV. At baseline all of the patients had normal liver function tests and low or undetectable HBVDNA levels, except
for those with chronic active hepatitis. Thirteen patients received prophylaxis with lamivudine, and 4 received treatment
with adefovir or tenofovir. At the end of the 24-month followup period, 49 patients were being treated. Data from 316 fol-
lowup visits showed that abatacept was safe. No patients experienced reactivation of hepatitis B. Treatment withdrawals
(23 patients) were due to lack of efficacy, subject decision/lost at followup, or adverse events not related to HBV infection.
Conclusion. Our study provides reassuring data about the safety profile of abatacept in RA with concomitant HBV infec-
tion without universal antiviral prophylaxis. Further prospective studies are needed to confirm these preliminary results.
INTRODUCTION
Hepatitis B virus (HBV) can cause chronic disease in 5% of
immunocompetent adults and has a worldwide prevalence of
more than 350 million persons. It is a leading cause of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma, and accounts
for more than 600,000 deaths every year (1). Treatment of rheu-
matoid arthritis (RA) patients with concomitant HBV is a
clinical challenge. Conventional synthetic disease-modifying
antirheumatic drugs (csDMARDs) could be associated with
increased hepatotoxicity, and biologic DMARDs (bDMARDs), in
particular tumor necrosis factor (TNF) blockers and anti-CD20
monoclonal antibodies, as well as newer drugs like tocilizumab
and abatacept, should be closely monitored for the possible reac-
tivation of B hepatitis (2–18). Abatacept is a soluble fusion pro-
tein of the extracellular domain of CTLA-4 and the Fc portion of
IgG1 (19). CTLA-4 is naturally expressed on T cells for regulato-
ry function and acts as a competitive inhibitor to prevent the co-
stimulatory activation of T cells involved in RA pathogenesis
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and in the modulation of HBV replication (20,21). Few and
sometimes conflicting data concerning the safety of abatacept in
RA patients with concomitant HBV infection arise from reviews
of short medical records or anecdotal cases. A study found that
it was safe and feasible only with antiviral prophylaxis in 4 of
8 patients (22). Two case reports described hepatitis B reactiva-
tion following treatment with abatacept (23,24). In a small case
series of 9 RA patients, 1 case of HBV reactivation is described
in a chronic inactive carrier (25).
The aim of this long-term, multicenter, retrospective
observational study was to verify the safety of abatacept in
a group of Italian RA patients with serologic evidence of
past or present HBV infection in a “real-life” setting.
MATERIALS AND METHODS
Eleven rheumatologic centers from different geographic areas
of Italy were invited to participate, i.e., provide retrospective
data about patients fulfilling the 1987 revised criteria of the
American College of Rheumatology for RA (26) and HBV-
positive serology treated with abatacept. Medical history,
clinical and laboratory data were retrieved from hospital
records, patient folders, and clinical charts and stored in a
dedicated database. Baseline data included demographic
information, disease duration, comorbidities, concomitant
drugs, previous csDMARDs and bDMARDs, Disease Activity
Score in 28 joints (DAS28) (27), rheumatoid factor and anti–
cyclic citrullinated protein antibody status, liver function
tests (LFTs) measured by alanine aminotransferase and aspar-
tate aminotransferase levels (units/liter), serologic B hepatitis
markers (hepatitis B surface antigen [HBsAg], hepatitis B sur-
face antibody [HBsAb], anti-HBe, hepatitis B core antibody
[HBcAb], and HBV DNA [IU/ml]), and hepatitis C virus
(HCV) co-infection markers (anti–hepatitis C antibodies and
HCV RNA). Antibody levels were determined using commer-
cial immunoassay tests commonly used in each study center
(most common was Abbott Architect, Abbott Diagnostics).
Serum HBV DNA was measured by polymerase chain reac-
tion assay, using different commercial kits in each study cen-
ter. The most commonly used were 1) COBAS Amplicor HBV
Monitor Test, version 2.0, Roche Diagnostics, with a lower
limit of quantification of 71 IU/ml; 2) COBAS TaqMan HBV
Test, version 2.0, Roche Molecular Systems, with a lower lim-
it of quantification of 12 IU/ml; 3) COBAS TaqMan HBV,
CTM HBV test, Roche Diagnostics, with a lower limit of quan-
tification of 12 IU/ml; and 4) Abbott Real Time HBV, Abbott
m2000, with a lower limit of quantification of 4 UI/ml.
Followup data were checked every 3 months for up to
24 months and included DAS28 scores, HBV markers
(HBsAg, HBsAb, anti-HBe, HBcAb, and HBV DNA), LFT,
antiviral therapy, or prophylaxis, and all adverse events
(AEs) were recorded as well. Abatacept was administered
intravenously according to the approved manufacturer
schedules in agreement with standard of care, every 2
weeks for the first month and then monthly.
Following the European Association for the Study of the
Liver guidelines (28), baseline patients’ viral status profiles
were classified as chronic active disease, carriers of inactive
disease, or occult HBV carriers. Chronic active B hepatitis
was defined as persistent HBsAg positivity, HBV DNA levels
.2,000 IU/ml, persistently or intermittently high LFTs, and
HBeAg or anti-HBe positivity. The status of inactive carrier
was defined as having persistent HBsAg positivity, anti-HBe
positivity, HBV DNA levels,2,000 IU/ml, and normal LFTs.
The status of occult HBV carrier was defined as HBsAg nega-
tivity in serum with HBcAb reactivity or anti-HBe reactivity
in patients that did not receive the HBV vaccination, with
normal LFTs and undetectable or low HBV DNA levels
(below the sensitivity cutoff of the current assay). A reactiva-
tion in a chronic carrier was defined as a switch to chronic
hepatitis status; in an occult carrier the definition also
included HBsAg seroconversion on followup.
The qualitative variables were expressed as percentages
of positivity; the quantitative variables were expressed as
mean6SD.
RESULTS
Demographic and clinical data of the patients are summa-
rized in Table 1. Seventy-two patients (10 male and 62
female), with a mean age of 62.6 years (range 33–84 years)
and a mean6SD disease duration of 126 5 years with active
disease (mean6SD DAS28 score 6.4461.5), were included.
Before abatacept treatment, 45.8% had been previously
treated with 2 bDMARDs, 19.4% with 3, and 23.6% with 1
bDMARD. In 8 cases (11.1%) abatacept was the first
bDMARD. In combination with abatacept, patients received
csDMARDS (methotrexate 66.7%, leflunomide 6.9%, sul-
phasalazine 2.8%, or hydroxychloroquine 8.3%) associated
with low-dosage (#7.5 mg/day prednisone equivalent) glu-
cocorticoids (80.6%) or glucocorticoids alone (16.6%). Two
patients received abatacept in monotherapy (2.8%).
Table 1 describes the baseline HBV status and treatment:
47 patients (65.3%) were categorized as inactive carriers
and 21 patients (29.1%) as occult carriers (anti-core posi-
tive). Four patients (5.6%) had chronic active hepatitis.
At baseline all the patients had normal LFT and low or
undetectable HBV DNA levels, except for those with chron-
ic active hepatitis who had HBV DNA titers .2,000 IU/ml
Significance & Innovations
 The management strategy of rheumatoid arthritis
(RA) with concomitant hepatitis B virus (HBV) in-
fection is still debated due to the risk of HBV reac-
tivation under immunosuppressive treatment. This
study adds significant information to the existing
anecdotal literature and provides further evidence
about the management of these cases.
 This article describes an Italian retrospective
multicenter long-term observational study. This
report, obtained in a “real-life” setting, provides
encouraging data about a good safety profile of
abatacept in a large case series of 72 patients with
RA and HBV infection (with and without antivi-
ral prophylaxis) in a 24-month followup period.
No patients experienced HBV reactivation.
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(range 12,000–55,000 IU/ml). Thirteen patients (18%)
received antiviral prophylaxis with lamivudine (9 of 47
inactive carriers and 4 of 21 occult carriers). The majority of
inactive and occult carrier patients were treated with abata-
cept without antiviral prophylaxis. In all cases, tight lab-
oratory and clinical control, in collaboration with the
infectologist, was set in order to identify HBV reactivation
and to promptly start antiviral therapy. Due to the retro-
spective design of the study, the decision whether to start
or not start antiviral prophylaxis was considered in each
center on the basis of local expert opinion and risk stratifi-
cation. In all patients HBV DNA was undetectable and nor-
mal LFTs were recorded at the baseline and followup visits.
Four patients (5.6%) received antiviral treatment, 2 with
adefovir and 2 with tenofovir (all 4 were chronic hepatitis).
No significant differences were observed in LFTs, HBV
DNA levels, concomitant therapy, and number of previous
DMARDs between inactive carriers with and without lami-
vudine prophylaxis. Four patients (2 inactive carriers, 1
occult carrier, and 1 with chronic active hepatitis) were also
anti–HCV positive without active viral replication (HCV
RNA undetectable).
At the end of the 24-month followup period, a total of
316 followup visits were performed, and 49 patients
(68%) were still on treatment with abatacept (Table 2); a
decrease in the mean6SD DAS28 score (2.36 1.9) was
Table 2. Followup data*
3 months 6 months 12 months 24 months
Patients being treated (ongoing) 67 (93) 62 (86.1) 55 (76.3) 49 (68)
DAS28, mean6SD 4.666 1.5 2.46 1.8 2.106 1.6 2.361.9
HBV reactivation 0 0 0 0
LFTs increased 0 0 0 0
Abatacept withdrawal
Primary inefficacy 4 (5.6) 1 (1.4)
Loss of efficacy 3 (4.1) 1 (1.4) 3 (4.1)
AEs (unrelated to HBV) 2 (2.7) 1 (1.4) 3 (4.1)
Subject decision/lost to followup 1 (1.4) 4 (5.6)
* Values are the number (percentage) unless indicated otherwise. DAS285Disease Activity Score in 28 joints;
HBV5hepatitis B virus; LFTs5 liver function tests; AEs5 adverse events.
Table 1. Baseline characteristics*
Demographic/clinical data All
Inactive
carrier
Occult
carrier
Chronic active
hepatitis
Patients 72 47 (65.3) 21 (29.1) 4 (5.6)
Female:male ratio 62:10 26:21 11:10 2:2
Mean age, years 62.6 (range 33–84) 62.8 62.3 62.6
Disease duration, mean6SD years 126 5 156 2 1265 116 3
DAS28, mean6SD 6.446 1.5 6.26 1.5 6.661.2 6.46 1.4
RF positive 53 (73.6) 34 (72.3) 16 (76.1) 3 (75)
ACPA positive 51 (70.8) 33 (70.2) 15 (71.4) 3 (75)
2 previous biologic DMARDs 33 (45.8) 21 (44.6) 10 (47.6) 2 (50)
3 previous biologic DMARDs 14 (19.4) 9 (19.1) 4 (19) 1 (25)
1 prior biologic DMARD 17 (23.6) 11 (23.4) 5 (23.8) 1 (25)
No prior biologic DMARDs 8 (11.1) 6 (12.7) 2 (9.5) 0
Concomitant therapy
Abatacept monotherapy 2 (2.8) 1 (2.1) 1 (4.7) 0
Steroids (alone) 12 (16.6) 6 (12.7) 2 (9.5) 4 (100)
Steroids associated with csDMARDs 58 (80.6) 40 (85.1) 18 (85.7) 0
HBV viral load
HBV DNA .2,000 IU/ml 4 (5.6) 0 0 4 (100)
HBV DNA low or undetectable level 68 (94.4) 47 (100) 21 (100) 0
Antiviral prophylaxis/treatment
Lamivudine 13 (18) 9 (19.1) 4 (19) 0
Adefovir/tenofovir (chronic active hepatitis) 4 (5.6) 0 0 4 (100)
Concomitant hepatitis C
Anti-HCV antibodies 4 (5.6) 2 (4.2) 1 (4.7) 1 (25)
Detectable HCV RNA 0 0 0 0
* Values are the number (percentage) unless indicated otherwise. DAS285Disease Activity Score in 28 joints; RF5 rheuma-
toid factor; ACPA5 anti–citrullinated protein antibodies; DMARDs5disease-modifying antirheumatic drugs;
csDMARDs5 conventional synthetic DMARDs; HBV5hepatitis B virus; HCV5hepatitis C virus.
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observed in those patients who continued the treatment.
In 316 LFT determinations and 158 HBV DNA determina-
tions recorded in 24 months, no patients experienced reacti-
vation of B hepatitis. Thirteen patients received lamivudine
while taking abatacept for all the time and a 24-months fol-
lowup was available (13 person-years); 38 inactive carriers
and 17 occult carriers received abatacept without lamivu-
dine prophylaxis, corresponding to 32 person-years (16.2
and 15.8 person-years, respectively); 4 chronic active hepati-
tis patients received abatacept with concomitant antiviral
treatment (2 tenofovir and 2 adefovir) for all the time, with a
24-month followup available (4 person-years). LFTs re-
mained normal and HBV serology remained unchanged. In
the 4 active carriers, HBV DNA titers became undetectable
between 4 and 6 months after antiviral treatment and abata-
cept initiation, remaining within the normal limits through-
out the subsequent 18-month followup. No differences have
been observed between patients treated with combination
therapy or monotherapy for RA. Five patients discontinued
treatment with abatacept for primary inefficacy, 7 for loss of
efficacy, 5 for subject decision/lost at followup, and 6 for
AEs (none related to HBV; chronic infected skin ulcer, post-
surgery acute renal failure for hip fracture, suspected demye-
linating disease, and urinary tract or respiratory recurrent
infections) (Table 2).
Additional data were available for 28 patients who
remained on treatment with abatacept for more than 24
months with no signs of HBV reactivation for up to 54 months
of followup (reaching a total cumulative count of 812 fol-
lowup visits). The prophylactic antiviral treatment was con-
tinued for all the period of exposure to abatacept and/or 6
months after treatment discontinuation (data not shown).
Data were also available for 20 of 23 patients who discon-
tinued abatacept with no signs of HBV reactivation for up to
27 additional average months of followup. Six of these 20
patients switched to TNF blockers, 6 switched to tocilizu-
mab, 4 to rituximab, and 4 to csDMARDs. In this group of
patients, 18 were occult carriers and 2 were inactive car-
riers. The prophylactic antiviral treatment was continued
in all patients in whom it was already ongoing (3 occult car-
riers and 1 inactive carrier) in those switching to TNF block-
ers or swapping to tocilizumab for all the time of exposure
to the new biologic treatment and/or 6 months after treat-
ment discontinuation. In 1 occult carrier who switched to
rituximab, the prophylactic antiviral treatment with lami-
vudine was started at the moment of changing therapy.
DISCUSSION
Our report supports a favorable safety profile of abatacept in
RA patients with positive HBV infection serology, either man-
aged with HBV prophylaxis or treatment and without. To the
best of our knowledge this is the first long-term, retrospective
multicenter observational case series of patients concerning
the use of abatacept in a “real-life” setting of RA patients with
serologic evidence of past or present HBV infection.
The prevalence of hepatitis varies widely, but even in areas
with low endemic levels it is essential to identify RA patients
who are or have been infected with HBV, because present or
past infection can have a considerable impact on morbidity
and clinical outcomes (1). This is particularly true in the case
of candidates for immunosuppressive treatment (5,29,30),
which may increase viral load or lead to viral reactivation in
patients with undiagnosed viral hepatitis (10,13,14).
Reactivation of HBV, even in occult carriers, is one of
the emerging problems in RA patients undergoing immu-
nosuppressive treatment, especially with old and newer
bDMARDs (17). There have been reports about HBV reacti-
vation in patients with a history of occult HBV infection
(i.e., negative for HBsAg but positive for antibody anti-
HBc and/or antibody to HBsAg) receiving immunosup-
pressive therapy and/or chemotherapy for autoimmune
diseases, organ transplantation, or malignancy (2–18).
The management strategy of RA patients with a history of
HBV infection receiving csDMARDs or bDMARDs is a still
debated issue. Data from literature are conflicting. To date, no
formal guidelines exist regarding screening, monitoring, and
management in the field of rheumatology. Different scientific
societies, in the fields of rheumatology, virology, and hepatol-
ogy, have identified this focus as a substantial concern and
each has provided their own recommendations (14,28–39).
The management varies according to immunosuppres-
sive agent and HBV infection profile (chronic carrier or
serologic sequelae of hepatitis B). If HBV infection is
active or re-activated, in either case antiviral therapy must
be initiated promptly, as soon as HBV DNA becomes
detectable. Concomitant immunosuppressive treatment
must be delayed or withdrawn.
The European League Against Rheumatism recommen-
dations contraindicate each treatment with biologic drugs
in patients with untreated chronic hepatitis B or with
treated chronic hepatitis B with Child-Pugh class B or
higher and advocate vaccination against hepatitis B in all
patients (38,39).
Abatacept is a soluble fusion protein that binds the CTLA-
4 extracellular domain to the Fc region of the IgG molecule.
CTLA-4 is an inhibitory T cell receptor, with a molecular
structure similar to CD28, expressed by activated and regula-
tory T cells (Tregs). CTLA-4 is constitutively expressed on
CD41 CD251 Tregs, and such expression is important for
Treg-mediated suppression of T cell proliferation (19).
Through the inhibition of the co-stimulatory signaling of T
cells in RA, abatacept has demonstrated clinical efficacy. It
is well known that the outcome of HBV infection varies,
depending on the efficiency of the immune response, a pro-
cess that is regulated by a number of molecules, including
CTLA-4 (13). However, the role of CTLA-4 in the pathogene-
sis of liver damage and hepatitis B replication is still
unknown: single-nucleotide polymorphisms in the CTLA-4
gene may be associated with HBV progression and viral per-
sistence, especially in the Asian population (40). There is
also evidence that CTLA-4 blockade could form one arm of a
therapeutic approach to modulate the different patterns of
co-regulation of T cell exhaustion in this heterogeneous dis-
ease (41). Finally, in a case–control study, inactive carriers
showed a higher increased inhibitory co-stimulation than
subjects with chronic active hepatitis (42).
Abatacept has only been associated with the reactiva-
tion of HBV infection in the few case reports mentioned
above (22–25). In a retrospective analysis of 8 patients
with RA and chronic hepatitis B (6 inactive carriers and 2
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chronic active hepatitis B) treated with abatacept, the drug
was shown to be safe in only 4 patients who were treated
with antiviral prophylaxis (22). RA improved in these
patients, as evidenced by a statistically significant decrease
in DAS28 scores, and none of the patients had reactivation of
hepatitis B. In the remaining 4 patients without antiviral pro-
phylaxis, there was no significant decrease in the DAS28
scores and all of them experienced reactivation of hepatitis B.
Two other case reports described hepatitis B reactivation fol-
lowing treatment with abatacept for RA. In one case the
patient was an occult carrier with a previous history of long-
term treatment with glucocorticoids, csDMARDs, and an
anti-TNF agent. The HBV reactivation occurred after 9
months of treatment with abatacept associated with glucocor-
ticoids and leflunomide, without antiviral prophylaxis (23).
The other case was an occult carrier with a 2-year history of
RA treated with csDMARDs for 1 year. The HBV reactivation
occurred after 10 months of treatment with abatacept without
antiviral prophylaxis (24).
In a recent Italian case series of 9 RA patients treated with
abatacept (8 with resolved HBV infection and 1 chronic inac-
tive carrier), 1 patient with chronic co-infection HCV started
lamivudine for LFT elevation occurring 2 months after abata-
cept initiation, with a gradual improvement of laboratory
levels along with persistently undetectable viral load, while
1 HBsAg-negative patient not receiving antiviral prophylaxis
developed HBV DNA positivity without aminotransferase
elevation at 12 months after starting abatacept (25).
There are no specific indications for management of HBV
infection in abatacept-treated patients. Recently, some
interesting recommendations for screening and treatment of
HBV infection in anti-TNF– and rituximab-treated patients
were proposed by Italian experts (43,44). The authors
advised the need for HBV infection screening before start-
ing anti-TNF therapy, as well as early treatment with nucle-
oside/nucleotide analogs and lamivudine prophylaxis in
HBV active and inactive carriers. Occult carriers (anti-HBc–
positive/HBsAg-negative patients) who have to undergo
TNF inhibitors do not need prophylaxis, but a tight control
is advised (HBsAg tests repeated every 3 months) in order
to identify HBV reactivation and to start antiviral therapy as
soon as possible (43). In the case of treatment with rituxi-
mab in occult patients, prophylaxis with lamivudine is rec-
ommended for those with oncohematologic diseases,
whereas watchful monitoring of HBsAg/HBV DNA levels is
advisable for all the other indications (44).
In our long-term, retrospective multicenter case series of
72 patients treated with abatacept in a “real-life” setting,
we provide encouraging data about safety in RA patients
with concomitant HBV-positive serology without universal
antiviral prophylaxis. No reactivation of hepatitis B was
observed in 47 inactive carriers and in 21 occult carriers
treated with abatacept for, respectively, 15.8 and 16.2
person-years without lamivudine prophylaxis. On the basis
of these observations, but taking into account a prudent
risk stratification, it could be reasonable to set the manage-
ment of patients with RA and HBV serology, who are candi-
dates for treatment with abatacept, according to what has
been previously proposed by the Italian experts for anti-
TNF (43,44): 1) treatment with nucleoside/nucleotide ana-
logs in patients with evidence of active hepatitis, 2) lamivu-
dine prophylaxis in inactive carriers before starting
abatacept, and 3) tight surveillance for the occult carrier.
However, taking into account the results of this study, cost
effectiveness of lamivudine prophylaxis in inactive carriers
could be assessed after a careful risk stratification. More
prospective data and shared expert opinion are needed to
confirm these preliminary results.
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